All Studies Meta Analysis Recent:

Bioinformatics study of curcumin, demethoxycurcumin, bisdemethoxycurcumin and cyclocurcumin compounds in Curcuma longa as an antiviral agent via nucleocapsid on SARS-CoV-2 inhibition

Hidayah et al., International Conference on Organic and Applied Chemistry, doi:10.1063/5.0197724

Feb 2024

Post
Facebook

Source PDF All Studies Meta AnalysisMeta

Curcumin for COVID-19

15th treatment shown to reduce risk in February 2021

^*, now with p = 0.0000000096 from 27 studies.

Lower risk for mortality, ventilation, hospitalization, progression, recovery, and viral clearance.

No treatment is 100% effective. Protocols combine treatments. ^* >10% efficacy, ≥3 studies.

4,500+ studies for 81 treatments. c19early.org

In Silico study showing binding of curcumin, demethoxycurcumin, bisdemethoxycurcumin and cyclocurcumin to the SARS-CoV-2 nucleocapsid protein. Authors find curcumin has the strongest predicted binding affinity. All compounds showed suitable pharmacokinetic properties. Binding is predicted to inhibit viral genome replication and transcription by disrupting ribonucleoprotein complex formation.

45 preclinical studies support the efficacy of curcumin for COVID-19:

24 In Silico studies1-24

20 In Vitro studies1,5,7,11,17,21,25-38

1 In Vivo animal study5

In Silico studies predict inhibition of SARS-CoV-2 with curcumin or metabolites via binding to the spikeA,5,10,12,18,21 (and specifically the receptor binding domainB,8,11,14), M^proC,5,7,9-11,13,14,16,19,21,22,24,35, RNA-dependent RNA polymeraseD,11,20, ACE2E,12,13,15, nucleocapsidF,6,23, nsp10G,23, and helicaseH,25 proteins. In Vitro studies demonstrate inhibition of the spikeA,30 (and specifically the receptor binding domainB,38), M^proC,17,30,35,37, ACE2E,38, and TMPRSS2I,38 proteins. In Vitro studies demonstrate efficacy in Calu-3J,36, A549K,30, 293TL,1, HEK293-hACE2M,17,28, 293T/hACE2/TMPRSS2N,29, Vero E6O,7,11,21,28,30-32,34,36, and SH-SY5YP,27 cells. Curcumin is predicted to inhibit the interaction between the SARS-CoV-2 spike protein receptor binding domain and the human ACE2 receptor for the delta and omicron variants8, decreases pro-inflammatory cytokines induced by SARS-CoV-2 in peripheral blood mononuclear cells34, and alleviates SARS-CoV-2 spike protein-induced mitochondrial membrane damage and oxidative stress1.

Important missing comments or errors? Let us know.

1. Zhang et al., Computational Discovery of Mitochondrial Dysfunction Biomarkers in Severe SARS-CoV-2 Infection: Facilitating Pytomedicine Screening, Phytomedicine, doi:10.1016/j.phymed.2024.155784.sciencedirect.com, doi.org.

2. Öztürkkan et al., In Silico investigation of the effects of curcuminoids on the spike protein of the omicron variant of SARS-CoV-2, Baku State University Journal of Chemistry and Material Sciences, 1:2, bsuj.bsu.edu.az/uploads/pdf/ec4204d62f7802de54e6092bf7860029.pdf.edu.az.

3. Yunze et al., Therapeutic effect and potential mechanism of curcumin, an active ingredient in Tongnao Decoction, on COVID-19 combined with stroke: a network pharmacology study and GEO database mining, Research Square, doi:10.21203/rs.3.rs-4329762/v1.researchsquare.com, doi.org.

4. Agamah et al., Network-based multi-omics-disease-drug associations reveal drug repurposing candidates for COVID-19 disease phases, ScienceOpen, doi:10.58647/DRUGARXIV.PR000010.v1.scienceopen.com, doi.org.

5. Boseila et al., Throat spray formulated with virucidal Pharmaceutical excipients as an effective early prophylactic or treatment strategy against pharyngitis post-exposure to SARS CoV-2, European Journal of Pharmaceutics and Biopharmaceutics, doi:10.1016/j.ejpb.2024.114279.sciencedirect.com, doi.org.

6. Hidayah et al., Bioinformatics study of curcumin, demethoxycurcumin, bisdemethoxycurcumin and cyclocurcumin compounds in Curcuma longa as an antiviral agent via nucleocapsid on SARS-CoV-2 inhibition, International Conference on Organic and Applied Chemistry, doi:10.1063/5.0197724.aip.org, doi.org.

7. Singh et al., Unlocking the potential of phytochemicals in inhibiting SARS-CoV-2 M Pro protein - An in-silico and cell-based approach, Research Square, doi:10.21203/rs.3.rs-3888947/v1.researchsquare.com, doi.org.

8. Kant et al., Structure-based drug discovery to identify SARS-CoV2 spike protein–ACE2 interaction inhibitors, Journal of Biomolecular Structure and Dynamics, doi:10.1080/07391102.2023.2300060.tandfonline.com, doi.org.

9. Naderi Beni et al., In silico studies of anti-oxidative and hot temperament-based phytochemicals as natural inhibitors of SARS-CoV-2 Mpro, PLOS ONE, doi:10.1371/journal.pone.0295014.plos.org, doi.org.

10. Moschovou et al., Exploring the Binding Effects of Natural Products and Antihypertensive Drugs on SARS-CoV-2: An In Silico Investigation of Main Protease and Spike Protein, International Journal of Molecular Sciences, doi:10.3390/ijms242115894.mdpi.com, doi.org.

11. Eleraky et al., Curcumin Transferosome-Loaded Thermosensitive Intranasal in situ Gel as Prospective Antiviral Therapy for SARS-Cov-2, International Journal of Nanomedicine, doi:10.2147/IJN.S423251.dovepress.com, doi.org.

12. Singh (B) et al., Computational studies to analyze effect of curcumin inhibition on coronavirus D614G mutated spike protein, The Seybold Report, doi:10.17605/OSF.IO/TKEXJ.ac.in, doi.org.

13. Thapa et al., In-silico Approach for Predicting the Inhibitory Effect of Home Remedies on Severe Acute Respiratory Syndrome Coronavirus-2, Makara Journal of Science, doi:10.7454/mss.v27i3.1609.ac.id, doi.org.

14. Srivastava et al., Paradigm of Well-Orchestrated Pharmacokinetic Properties of Curcuminoids Relative to Conventional Drugs for the Inactivation of SARS-CoV-2 Receptors: An In Silico Approach, Stresses, doi:10.3390/stresses3030043.mdpi.com, doi.org.

15. Alkafaas et al., A study on the effect of natural products against the transmission of B.1.1.529 Omicron, Virology Journal, doi:10.1186/s12985-023-02160-6.biomedcentral.com, doi.org.

16. Winih Kinasih et al., Analisis in silico interaksi senyawa kurkuminoid terhadap enzim main protease 6LU7 dari SARS-CoV-2, Duta Pharma Journal, doi:10.47701/djp.v3i1.2904.ac.id, doi.org.

17. Wu et al., Potential Mechanism of Curcumin and Resveratrol against SARS-CoV-2, Research Square, doi:10.21203/rs.3.rs-2780614/v1.researchsquare.com, doi.org.

18. Nag et al., Curcumin inhibits spike protein of new SARS-CoV-2 variant of concern (VOC) Omicron, an in silico study, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.105552.sciencedirect.com, doi.org.

19. Rampogu et al., Molecular Docking and Molecular Dynamics Simulations Discover Curcumin Analogue as a Plausible Dual Inhibitor for SARS-CoV-2, International Journal of Molecular Sciences, doi:10.3390/ijms23031771.mdpi.com, doi.org.

20. Singh (C) et al., Potential of turmeric-derived compounds against RNA-dependent RNA polymerase of SARS-CoV-2: An in-silico approach, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2021.104965.sciencedirect.com, doi.org.

21. Kandeil et al., Bioactive Polyphenolic Compounds Showing Strong Antiviral Activities against Severe Acute Respiratory Syndrome Coronavirus 2, Pathogens, doi:10.3390/pathogens10060758.mdpi.com, doi.org.

22. Rajagopal et al., Activity of phytochemical constituents of Curcuma longa (turmeric) and Andrographis paniculata against coronavirus (COVID-19): an in silico approach, Future Journal of Pharmaceutical Sciences, doi:10.1186/s43094-020-00126-x.springeropen.com, doi.org.

23. Suravajhala et al., Comparative Docking Studies on Curcumin with COVID-19 Proteins, MDPI AG, doi:10.20944/preprints202005.0439.v3.preprints.org, doi.org.

24. Sekiou et al., In-Silico Identification of Potent Inhibitors of COVID-19 Main Protease (Mpro) and Angiotensin Converting Enzyme 2 (ACE2) from Natural Products: Quercetin, Hispidulin, and Cirsimaritin Exhibited Better Potential Inhibition than Hydroxy-Chloroquine Against COVID-19 Main Protease Active Site and ACE2, ChemRxiv, doi:10.26434/chemrxiv.12181404.v1.chemrxiv.org, doi.org.

25. Li et al., Thermal shift assay (TSA)-based drug screening strategy for rapid discovery of inhibitors against the Nsp13 helicase of SARS-CoV-2, Animals and Zoonoses, doi:10.1016/j.azn.2024.06.001.sciencedirect.com, doi.org.

26. Kamble et al., Nanoparticulate curcumin spray imparts prophylactic and therapeutic properties against SARS-CoV-2, Emergent Materials, doi:10.1007/s42247-024-00754-6.springer.com, doi.org.

27. Nicoliche et al., Antiviral, anti-inflammatory and antioxidant effects of curcumin and curcuminoids in SH-SY5Y cells infected by SARS-CoV-2, Scientific Reports, doi:10.1038/s41598-024-61662-7.nature.com, doi.org.

28. Nittayananta et al., A novel film spray containing curcumin inhibits SARS-CoV-2 and influenza virus infection and enhances mucosal immunity, Virology Journal, doi:10.1186/s12985-023-02282-x.biomedcentral.com, doi.org.

29. Septisetyani et al., Curcumin and turmeric extract inhibited SARS-CoV-2 pseudovirus cell entry and Spike mediated cell fusion, bioRxiv, doi:10.1101/2023.09.28.560070.biorxiv.org, doi.org.

30. Mohd Abd Razak et al., In Vitro Anti-SARS-CoV-2 Activities of Curcumin and Selected Phenolic Compounds, Natural Product Communications, doi:10.1177/1934578X231188861.sagepub.com, doi.org.

31. Teshima et al., Antiviral activity of curcumin and its analogs selected by an artificial intelligence-supported activity prediction system in SARS-CoV-2-infected VeroE6 cells, Natural Product Research, doi:10.1080/14786419.2023.2194647.tandfonline.com, doi.org.

32. Leka et al., In vitro antiviral activity against SARS-CoV-2 of common herbal medicinal extracts and their bioactive compounds, Phytotherapy Research, doi:10.1002/ptr.7463.wiley.com, doi.org.

33. Goc et al., Inhibitory effects of specific combination of natural compounds against SARS-CoV-2 and its Alpha, Beta, Gamma, Delta, Kappa, and Mu variants, European Journal of Microbiology and Immunology, doi:10.1556/1886.2021.00022.akjournals.com, doi.org.

34. Marín-Palma et al., Curcumin Inhibits In Vitro SARS-CoV-2 Infection In Vero E6 Cells through Multiple Antiviral Mechanisms, Molecules, doi:10.3390/molecules26226900.mdpi.com, doi.org.

35. Bahun et al., Inhibition of the SARS-CoV-2 3CLpro main protease by plant polyphenols, Food Chemistry, doi:10.1016/j.foodchem.2021.131594.sciencedirect.com, doi.org.

36. Bormann et al., Turmeric Root and Its Bioactive Ingredient Curcumin Effectively Neutralize SARS-CoV-2 In Vitro, Viruses, doi:10.3390/v13101914.mdpi.com, doi.org.

37. Guijarro-Real et al., Potential In Vitro Inhibition of Selected Plant Extracts against SARS-CoV-2 Chymotripsin-Like Protease (3CLPro) Activity, Foods, doi:10.3390/foods10071503.mdpi.com, doi.org.

38. Goc (B) et al., Phenolic compounds disrupt spike-mediated receptor-binding and entry of SARS-CoV-2 pseudo-virions, PLOS ONE, doi:10.1371/journal.pone.0253489.plos.org, doi.org.

a. The trimeric spike (S) protein is a glycoprotein that mediates viral entry by binding to the host ACE2 receptor, is critical for SARS-CoV-2's ability to infect host cells, and is a target of neutralizing antibodies. Inhibition of the spike protein prevents viral attachment, halting infection at the earliest stage.

b. The receptor binding domain is a specific region of the spike protein that binds ACE2 and is a major target of neutralizing antibodies. Focusing on the precise binding site allows highly specific disruption of viral attachment with reduced potential for off-target effects.

c. The main protease or M^pro, also known as 3CL^pro or nsp5, is a cysteine protease that cleaves viral polyproteins into functional units needed for replication. Inhibiting M^pro disrupts the SARS-CoV-2 lifecycle within the host cell, preventing the creation of new copies.

d. RNA-dependent RNA polymerase (RdRp), also called nsp12, is the core enzyme of the viral replicase-transcriptase complex that copies the positive-sense viral RNA genome into negative-sense templates for progeny RNA synthesis. Inhibiting RdRp blocks viral genome replication and transcription.

e. The angiotensin converting enzyme 2 (ACE2) protein is a host cell transmembrane protein that serves as the cellular receptor for the SARS-CoV-2 spike protein. ACE2 is expressed on many cell types, including epithelial cells in the lungs, and allows the virus to enter and infect host cells. Inhibition may affect ACE2's physiological function in blood pressure control.

f. The nucleocapsid (N) protein binds and encapsulates the viral genome by coating the viral RNA. N enables formation and release of infectious virions and plays additional roles in viral replication and pathogenesis. N is also an immunodominant antigen used in diagnostic assays.

g. Non-structural protein 10 (nsp10) serves as an RNA chaperone and stabilizes conformations of nsp12 and nsp14 in the replicase-transcriptase complex, which synthesizes new viral RNAs. Nsp10 disruption may destabilize replicase-transcriptase complex activity.

h. The helicase, or nsp13, protein unwinds the double-stranded viral RNA, a crucial step in replication and transcription. Inhibition may prevent viral genome replication and the creation of new virus components.

i. Transmembrane protease serine 2 (TMPRSS2) is a host cell protease that primes the spike protein, facilitating cellular entry. TMPRSS2 activity helps enable cleavage of the spike protein required for membrane fusion and virus entry. Inhibition may especially protect respiratory epithelial cells, buy may have physiological effects.

j. Calu-3 is a human lung adenocarcinoma cell line with moderate ACE2 and TMPRSS2 expression and SARS-CoV-2 susceptibility. It provides a model of the human respiratory epithelium, but many not be ideal for modeling early stages of infection due to the moderate expression levels of ACE2 and TMPRSS2.

k. A549 is a human lung carcinoma cell line with low ACE2 expression and SARS-CoV-2 susceptibility. Viral entry/replication can be studied but the cells may not replicate all aspects of lung infection.

l. 293T is a human embryonic kidney cell line that can be engineered for high ACE2 expression and SARS-CoV-2 susceptibility. 293T cells are easily transfected and support high protein expression.

m. HEK293-hACE2 is a human embryonic kidney cell line with high ACE2 expression and SARS-CoV-2 susceptibility. Cells have been transfected with a plasmid to express the human ACE2 (hACE2) protein.

n. 293T/hACE2/TMPRSS2 is a human embryonic kidney cell line engineered for high ACE2 and TMPRSS2 expression, which mimics key aspects of human infection. 293T/hACE2/TMPRSS2 cells are very susceptible to SARS-CoV-2 infection.

o. Vero E6 is an African green monkey kidney cell line with low/no ACE2 expression and high SARS-CoV-2 susceptibility. The cell line is easy to maintain and supports robust viral replication, however the monkey origin may not accurately represent human responses.

p. SH-SY5Y is a human neuroblastoma cell line that exhibits neuronal phenotypes. It is commonly used as an in vitro model for studying neurotoxicity, neurodegenerative diseases, and neuronal differentiation.

Hidayah et al., 6 Feb 2024, peer-reviewed, 3 authors. Contact: rizkanurulh@student.ub.ac.id, dewi.santosa@ub.ac.id, roihatulmutiah@gmail.com.

In Silico studies are an important part of preclinical research, however results may be very different in vivo.

This Paper Curcumin All

Bioinformatics study of curcumin, demethoxycurcumin, bisdemethoxycurcumin and cyclocurcumin compounds in Curcuma longa as an antiviral agent via nucleocapsid on SARS-CoV-2 inhibition

Rizka Nurul Hidayah, Dewi Santosaningsih, Roihatul Muti’ah

doi:10.1063/5.0197724

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a higher reproduction rate (R0) than SARS-CoV-1 is assessed to be 2.5 contrasted with 2.0-3.0 for SARS-CoV, indicating a much faster spread. During the replication process, the viral ribonucleic acid (RNA) genome is bound to the nucleocapsid and packaged into a ribonucleoprotein complex (RNP) which is essential for maintaining RNA conformation for genome replication and copy. Antiviral agents are given to prevent the replication area from expanding. In silico simulation was used to predict an interaction between Curcuma longa compound as an Antiviral agent by inhibiting viral RNA transcription and replication through inhibiting the activity of the nucleocapsid during the screening of a new compound as a drug candidate. The Nucleocapsid structures were used to create the protein target from Protein Data Bank. PubChem online tool was used to determine the structure of Curcumin, Demethoxycurcumin, Bisdemethoxycurcumin, and Cyclocurcumin as ligands. With the help of software like pkCSM, Protox, and SwissADME, these structures are analyzed for pharmacokinetics and physicochemistry interactions. To predict the most probable compliance of how the ligand will tie to the macromolecule evaluated through the action of the compound in light of the Rerank Score using the Molegro Virtual Docker 6.0 software. When curcumin binds to 6VYO, it has the lowest bond energy (-73,8743 Kcal/mol) than the native ligand and comparison drug Chloroquine (-60.438 Kcal/mol and -59.062 Kcal/mol, respectively). These findings tend to inhibit the role of nucleocapsids in the binding of viral RNA genomes and the packaging process into ribonucleoprotein complexes (RNPs), leading to the prevention of viral infection, replication, and packaging processes of the virus.

References

Allen, Mervin, Mahmoud, Bender, None, J Cheminform, doi:10.1186/s13321-019-0356-5

Ashraf, Sultan, Campus, Alam, Darul Ehsan, None, International Journal of Green Pharmacy

Askarizadeh, Barreto, Henney, Majeed, Sahebkar, None, International Journal of Pharmaceutics, doi:10.1016/j.ijpharm.2020.119476

Cevik, Kuppalli, Kindrachuk, Peiris, None, The BMJ

Chen, Li, Tian, Li, Luo et al., None, Journal of Computational Biology, doi:10.1089/cmb.2019.0323

Chen, None, Research on Chemical Intermediates, doi:10.1007/s11164-016-2583-y

Cong, None, J Virol, doi:10.1128/JVI.01925-19

Dona, Frimayanti, Ikhtiarudin, Iskandar, Maulana et al., None, Jurnal Sains Farmasi & Klinis, doi:10.25077/jsfk.6.3.243-249.2019

Fu, Chen, Zhang, Yu, Yang, None, Int. J. Mol. Med

Fu, Chen, Zhang, Yu, Yang, None, Int. J. Mol. Med, doi:10.3892/ijmm.2017.2926

Guan, None, New England Journal of Medicine, doi:10.1056/NEJMoa2002032

Hamm, None, Regulatory Toxicology and Pharmacology, doi:10.1016/j.yrtph.2021.105007

Kang, None, Acta Pharm Sin B

Khan, None, Comput Struct Biotechnol J, doi:10.1016/j.csbj.2020.08.006

Kwarteng, Asiedu, Sakyi, Asiedu, None, Biomedicine and Pharmacotherapy

Lang, Chen, Li, Li, None, Life Sciences, doi:10.1016/j.lfs.2020.118754

Marazzi, Francés-Monerris, Mourer, Pasc, Monari, None, Physical Chemistry Chemical Physics, doi:10.1039/C9CP06565B

Mazhir, Ali, Kadhim, Majeed, None, Journal of Physics

Megasari, None, PLoS One, doi:10.1371/journal.pone.0251234

Mitsuwan, None, Int J Parasitol Drugs Drug Resist, doi:10.1016/j.ijpddr.2020.11.001

Oyesakin, George, Fadare R Y, Idris, Fadare, None, Am J Pharmacol Sci

Petersen, None, Lancet Infect Dis, doi:10.1016/S1473-3099(20)30484-9

Rim, None, Toxicol Environ Health Sci, doi:10.1007/s13530-020-00056-4

Rothwell, None, The Journal of Biological Databases and Curation

Ruswanto, Wulandari, Rahayu, Mardaningrum, Hidayati, None, Pharmacosricpt

Santos, Ferreira, Caffarena, None, Methods in Molecular Biology, doi:10.1007/978-1-4939-9752-7_2

Shafhan Arfi, Lestari, Damayanti, None

Suhartati, Anugrah, Raharja, None

Syarif, None, Jurnal Kedokteran Brawijaya, doi:10.21776/ub.jkb.2016.029.01.7

Tung, Nham, Hai, Thu, None

Wang, None, RSC Adv, doi:10.1039/C6RA28442F

Wolfram, Trifan, None, Computational Phytochemistry

Wu, Ta, Lung, Weng, Leong, None, Pharmaceutics

Zeng, Deng, Dang, Yu, None, Sci Rep

{ 'indexed': {'date-parts': [[2024, 2, 8]], 'date-time': '2024-02-08T00:31:39Z', 'timestamp': 1707352299257}, 'reference-count': 34, 'publisher': 'AIP Publishing', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2024]]}, 'DOI': '10.1063/5.0197724', 'type': 'proceedings-article', 'created': {'date-parts': [[2024, 2, 7]], 'date-time': '2024-02-07T19:50:27Z', 'timestamp': 1707335427000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Bioinformatics study of curcumin, demethoxycurcumin, bisdemethoxycurcumin and cyclocurcumin ' 'compounds in Curcuma longa as an antiviral agent via nucleocapsid on SARS-CoV-2 inhibition', 'prefix': '10.1063', 'author': [ {'given': 'Rizka Nurul', 'family': 'Hidayah', 'sequence': 'first', 'affiliation': []}, {'given': 'Dewi', 'family': 'Santosaningsih', 'sequence': 'additional', 'affiliation': []}, {'given': 'Roihatul', 'family': 'Muti’ah', 'sequence': 'additional', 'affiliation': []}], 'member': '317', 'reference': [ { 'key': '10.1063/5.0197724_c1', 'doi-asserted-by': 'publisher', 'DOI': '10.1371/journal.pone.0251234'}, { 'key': '10.1063/5.0197724_c2', 'unstructured': 'M. Cevik, K. Kuppalli, J. Kindrachuk, and M. Peiris, The BMJ 371, ' '(2020).'}, { 'key': '10.1063/5.0197724_c3', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S1473-3099(20)30484-9'}, { 'key': '10.1063/5.0197724_c4', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2002032'}, { 'key': '10.1063/5.0197724_c5', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.lfs.2020.118754'}, { 'key': '10.1063/5.0197724_c6', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/JVI.01925-19'}, { 'key': '10.1063/5.0197724_c7', 'unstructured': 'S. Kang et al., Acta Pharm Sin B 10, 228–1238 (2020).'}, { 'key': '10.1063/5.0197724_c8', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ijpddr.2020.11.001'}, { 'key': '10.1063/5.0197724_c9', 'doi-asserted-by': 'crossref', 'unstructured': 'S. N. Mazhir, A. H. Ali, Q. A. Kadhim, and N. F. Majeed, Journal of ' 'Physics 1660 (2020).', 'DOI': '10.1088/1742-6596/1660/1/012042'}, { 'key': '10.1063/5.0197724_c10', 'unstructured': 'K. Ashraf, S. Sultan, P. Alam Campus, B. Puncak Alam, and S. Darul ' 'Ehsan, International Journal of Green Pharmacy 11 (2017).'}, { 'key': '10.1063/5.0197724_c11', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s11164-016-2583-y'}, { 'key': '10.1063/5.0197724_c12', 'doi-asserted-by': 'crossref', 'unstructured': 'E. Wolfram and A. Trifan, Computational Phytochemistry, 277–300 (2018).', 'DOI': '10.1016/B978-0-12-812364-5.00010-9'}, { 'key': '10.1063/5.0197724_c13', 'unstructured': 'Ruswanto., Wulandari, W. T., Rahayu, S. S., Mardaningrum, R., & ' 'Hidayati, N. D., Pharmacosricpt, 2, 1–12 (2019).'}, { 'key': '10.1063/5.0197724_c14', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/978-1-4939-9752-7_2'}, { 'key': '10.1063/5.0197724_c15', 'doi-asserted-by': 'publisher', 'DOI': '10.25077/jsfk.6.3.243-249.2019'}, { 'key': '10.1063/5.0197724_c16', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s13530-020-00056-4'}, { 'key': '10.1063/5.0197724_c17', 'unstructured': 'Kwarteng A., Asiedu E., Sakyi S.A., Asiedu S.O., Biomedicine and ' 'Pharmacotherapy 1 (2020).'}, { 'key': '10.1063/5.0197724_c18', 'doi-asserted-by': 'publisher', 'DOI': '10.1039/C6RA28442F'}, { 'key': '10.1063/5.0197724_c19', 'unstructured': 'Oyesakin Y M., George D E., Fadare R Y., Idris A Y., and O. A. Fadare, ' 'Am J Pharmacol Sci. 6, 25–32 (2018).'}, { 'key': '10.1063/5.0197724_c20', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ijpharm.2020.119476'}, { 'key': '10.1063/5.0197724_c21', 'doi-asserted-by': 'crossref', 'unstructured': 'R. Zeng, J. Deng, L. Dang, and X. Yu, Sci Rep. 11 (2021).', 'DOI': '10.1038/s41598-021-89587-5'}, { 'key': '10.1063/5.0197724_c22', 'unstructured': 'Y. W. Wu, G. H. Ta, Y. C. Lung, C. F. Weng, and M. K. Leong, ' 'Pharmaceutics, 14 (2022).'}, { 'key': '10.1063/5.0197724_c23', 'doi-asserted-by': 'publisher', 'DOI': '10.1089/cmb.2019.0323'}, { 'key': '10.1063/5.0197724_c24', 'doi-asserted-by': 'publisher', 'DOI': '10.1186/s13321-019-0356-5'}, { 'key': '10.1063/5.0197724_c25', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.yrtph.2021.105007'}, { 'key': '10.1063/5.0197724_c26', 'unstructured': 'A. Shafhan Arfi, R. Dian Lestari, and D. Sri Damayanti, Skripsi, ' 'Universitas Islam Malang, 2020'}, { 'key': '10.1063/5.0197724_c27', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.csbj.2020.08.006'}, { 'key': '10.1063/5.0197724_c28', 'doi-asserted-by': 'crossref', 'unstructured': 'B. T. Tung, D. T. Nham, N. T. Hai, and D. K. Thu, Elsevier, 2019, pp. ' '125–134.', 'DOI': '10.1016/B978-0-12-814466-4.00010-0'}, { 'key': '10.1063/5.0197724_c29', 'doi-asserted-by': 'publisher', 'DOI': '10.1039/C9CP06565B'}, { 'key': '10.1063/5.0197724_c30', 'doi-asserted-by': 'publisher', 'DOI': '10.3892/ijmm.2017.2926'}, { 'key': '10.1063/5.0197724_c31', 'doi-asserted-by': 'publisher', 'DOI': '10.21776/ub.jkb.2016.029.01.7'}, { 'key': '10.1063/5.0197724_c32', 'unstructured': 'J. A. Rothwell et al., The Journal of Biological Databases and Curation, ' '2013, 1–8 (2013).'}, { 'key': '10.1063/5.0197724_c33', 'unstructured': 'T. Suhartati, C.V. Anugrah Utama Raharja, Bandar Lampung, (2017).'}, { 'key': '10.1063/5.0197724_c34', 'doi-asserted-by': 'crossref', 'unstructured': 'M. Fu, L. Chen, L. Zhang, X. Yu, and Q. Yang, Int. J. Mol. Med. 39 ' '(2017) pp. 1164–1172.', 'DOI': '10.3892/ijmm.2017.2926'}], 'event': 'INTERNATIONAL CONFERENCE ON ORGANIC AND APPLIED CHEMISTRY (ICOAC) 2022', 'container-title': 'INTERNATIONAL CONFERENCE ON ORGANIC AND APPLIED CHEMISTRY (ICOAC) 2022', 'original-title': [], 'link': [ { 'URL': 'http://aip.scitation.org/doi/pdf/10.1063/5.0197724', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2024, 2, 7]], 'date-time': '2024-02-07T20:18:48Z', 'timestamp': 1707337128000}, 'score': 1, 'resource': {'primary': {'URL': 'https://pubs.aip.org/aip/acp/article-lookup/doi/10.1063/5.0197724'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2024]]}, 'references-count': 34, 'URL': 'http://dx.doi.org/10.1063/5.0197724', 'relation': {}, 'ISSN': ['0094-243X'], 'published': {'date-parts': [[2024]]}}

Download Image

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0